NR3C2 and hydrops fetalis: GDMTs for HF, including angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor neprilysin-inhibitors (ARNIs), mineralocorticoid-receptor-antagonists (MRAs), and beta-blocker, have not only proven to reduce cardiovascular outcomes and mortality, but have shown to improve cardiac structure and function [26,27,28,29,30,31].